Research
Hormonal
GLP-1 receptor agonists (liraglutide) have unclear clinical benefits in non-obese patients with Heart Failure with Reduced Ejection Fraction (HFrEF).
For non-obese HFrEF patients, GLP-1 agonists like liraglutide may not provide significant weight loss or clear clinical benefits based on current small trials. Consult your doctor about the specific relevance of these treatments for your condition.
LimitedQualifiesLOW confidence
In HFrEF, two trials in non-obese populations of the GLP-1 receptor agonist liraglutide achieved trivial weight loss (~ 2 kg); there were very small numbers of clinical endpoints in these trials, rendering unclear conclusions [14, 15].
Why this rating
Based on small trials with unclear conclusions and trivial weight loss.
Source
Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?
Matthew M.Y. Lee et al. · Current Heart Failure Reports · 2023
DOI 10.1007/s11897-023-00637-7
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (specifically semaglutide) produce substantial, sustained weight loss and improve health status in patients with heart failure with preserved ejection fraction (HFpEF).Good
- Caloric restriction through structured dietary interventions improves functional capacity and quality of life in patients with HFpEF.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →